29/06/2011 Dr. Simó participates in the meeting of the American Diabetes Association 29/06/2011 Dr. Rafael Simó, leader of the Diabetes and Metabolism group at Vall d'Hebron Research Institute (VHIR) has participated in one of the symposia of the meeting American Diabetes Association (ADA), which took place at San Diego, where has been analyzed the use of incretins in diabetes type 2 (DM2), and the future of insulins. During his speech, Dr. Simo said that "the goal is to individualize therapy, knowing that pursuing this figure does not always translate into increased survival", referring to the idea of always maintaining glycosylated hemoglobin (HbA1c ) at levels of 7 in all patients. "The guides are not always right and the tests are not the real world", he stated. Dr. Rafael Simó, leader of the Diabetes and Metabolism group at Vall d'Hebron Research Institute (VHIR) has participated in one of the symposia of the meeting American Diabetes Association (ADA), which took place at San Diego, where has been analyzed the use of incretins in diabetes type 2 (DM2), and the future of insulins. During his speech, Dr. Simo said that "the goal is to individualize therapy, knowing that pursuing this figure does not always translate into increased survival", referring to the idea of always maintaining glycosylated hemoglobin (HbA1c ) at levels of 7 in all patients. "The guides are not always right and the tests are not the real world", he stated. Twitter LinkedIn Facebook Whatsapp
